# Esther Bridges

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 21 papers | 948 citations | 14 h-index | 24 g-index |
| 24 ext. papers | 1,173 ext. citations | 8.9 avg, IF | 3.61 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 21 | Proline synthesis through PYCR1 is required to support cancer cell proliferation and survival in oxygen-limiting conditions.. *Cell Reports*, **2022**, 38, 110320 | 10.6 | 1 |
| 20 | Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer. *British Journal of Cancer*, **2021**, 125, 534-546 | 8.7 | 1 |
| 19 | Differential effects of HIF2 antagonist and HIF2 silencing in renal cancer and sensitivity to repurposed drugs. *BMC Cancer*, **2021**, 21, 896 | 4.8 | 0 |
| 18 | ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression. *Molecular Cancer Research*, **2021**, 19, 1957-1969 | 6.6 | 0 |
| 17 | RHOQ is induced by DLL4 and regulates angiogenesis by determining the intracellular route of the Notch intracellular domain. *Angiogenesis*, **2020**, 23, 493-513 | 10.6 | 16 |
| 16 | Disruption of hypoxia-inducible fatty acid binding protein 7 induces beige fat-like differentiation and thermogenesis in breast cancer cells. *Cancer & Metabolism*, **2020**, 8, 13 | 5.4 | 7 |
| 15 | Hypoxia Induces Transcriptional and Translational Downregulation of the Type I IFN Pathway in Multiple Cancer Cell Types. *Cancer Research*, **2020**, 80, 5245-5256 | 10.1 | 14 |
| 14 | Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 12452-12461 | 11.5 | 53 |
| 13 | Adaptation to HIF1 Deletion in Hypoxic Cancer Cells by Upregulation of GLUT14 and Creatine Metabolism. *Molecular Cancer Research*, **2019**, 17, 1531-1544 | 6.6 | 14 |
| 12 | Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth. *Oncotarget*, **2017** , 8, 40115-40131 | 3.3 | 24 |
| 11 | MEF2 transcription factors are key regulators of sprouting angiogenesis. *Genes and Development*, **2016**, 30, 2297-2309 | 12.6 | 45 |
| 10 | Disrupting Hypoxia-Induced Bicarbonate Transport Acidifies Tumor Cells and Suppresses Tumor Growth. *Cancer Research*, **2016**, 76, 3744-55 | 10.1 | 63 |
| 9 | PI3K-mTORC2 but not PI3K-mTORC1 regulates transcription of HIF2A/EPAS1 and vascularization in neuroblastoma. *Cancer Research*, **2015**, 75, 4617-28 | 10.1 | 56 |
| 8 | Estrogen receptor- directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 15172-7 | 11.5 | 74 |
| 7 | Vascular-promoting therapy reduced tumor growth and progression by improving chemotherapy efficacy. *Cancer Cell*, **2015**, 27, 7-9 | 24.3 | 22 |
| 6 | Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. *Oncotarget*, **2014**, 5, 5934-49 | 3.3 | 48 |
| 5 | ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. *Oncotarget*, **2014**, 5, 6633-46 | 3.3 | 54 |

| | | | |
|---|---|---|---|
| 4 | Fatty acid-binding protein 4, a point of convergence for angiogenic and metabolic signaling pathways in endothelial cells. *Journal of Biological Chemistry*, **2014**, 289, 23168-23176 | 5.4 | 63 |
| 3 | A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. *Cancer Cell*, **2013**, 24, 229-41 | 24.3 | 164 |
| 2 | Notch regulation of tumor angiogenesis. *Future Oncology*, **2011**, 7, 569-88 | 3.6 | 48 |
| 1 | DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. *Cancer Research*, **2011**, 71, 6073-83 | 10.1 | 181 |